Company intelligence / Profile preview

Azemidite Biopharm

Ownership: Private
Development stage: Commercial

Overview

Azemidite Biopharm is a global leader in oligonucleotide R&D, specializing in siRNA therapeutics. The company has six internally discovered drug assets in clinical trials for seven indications across cardiovascular, metabolic, renal, and liver disease areas. Four of these are in Phase 2 trials. Its lead asset RBD4059 targets FXI for thrombotic disease and is the most advanced siRNA drug globally for this indication. Other key programs target APOC3 for lipid metabolism disorders and HBsAg for hepatitis B/D functional cure strategies[2][3].

Therapeutic areas: Metabolic DisordersCardiovascularGastroenterologyNephrology
Modalities: Small interfering RNAOligonucleotide therapyRNA therapy
Industry: Biotech

Beyond the preview

Go deeper on Azemidite Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azemidite Biopharm.

Explore the full profile